Jeffrey Kaine
About
In The Last Decade
Jeffrey Kaine
38 papers receiving 1.8k citations
Peers
Comparison fields: 5 of 105
- Rheumatology 1.1k
- Immunology 580
- Hematology 404
- Radiology, Nuclear Medicine and Imaging 306
- Genetics 272
Countries citing papers authored by Jeffrey Kaine
This map shows the geographic impact of Jeffrey Kaine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Kaine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Kaine more than expected).
Fields of papers citing papers by Jeffrey Kaine
This network shows the impact of papers produced by Jeffrey Kaine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Kaine. The network helps show where Jeffrey Kaine may publish in the future.
Co-authorship network of co-authors of Jeffrey Kaine
This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Kaine. A scholar is included among the top collaborators of Jeffrey Kaine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Kaine. Jeffrey Kaine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 18 | |
| 2 | 77 | |
| 3 | 33 | |
| 4 | 79 | |
| 5 | 14 | |
| 6 | 43 | |
| 7 | 1 | |
| 8 | Prolonged Exposure to Subcutaneous and Intravenous Abatacept in Patients with Rheumatoid Arthritis does not Affect Rates of Infection, Malignancy and Autoimmune Events: Results from Pooled Clinical Trial Data | 1 |
| 9 | Safety profile of subcutaneous abatacept focusing On clinically relevant events in patients with rheumatoid arthritis and up to 4.5 years of exposure | 3 |
| 10 | Efficacy, safety and pharmacokinetics of subcutaneous abatacept in patients with rheumatoid arthritis, with or without an intravenous loading dose | 4 |
| 11 | 73 | |
| 12 | 63 | |
| 13 | 157 | |
| 14 | 54 | |
| 15 | 84 | |
| 16 | 13 | |
| 17 | 123 | |
| 18 | 62 | |
| 19 | 77 | |
| 20 | 7 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.